5Fareed J, Hoppensteadt DA. Pharmacology of low molecular weight heparine. Semin Thromb Hemost, 1996,22 (Suppl 2 ) : 13-18.
6Buchwald AB, Hammerschmidt S, Stevens, et al. Inhibition of neointimal proliteration after coronary angioplasty by low molecular weight heparin (clivarine) and polyethycolhirudin [J].J Cardiovasc Pharmacol, 1996, 28 (24): 481-487.
7Bara L, Mardiguian J, Samam M. In vitro effect on heptest of low molecular weight heparin fractions and preparations with various anti- Ⅱ a and anti- Ⅱ activities [J]. Thromb Res, 1990, 57: 585.
8Ejiri M, Miawa K, et al. Effects of heparil treatment or collateral development and regional myocardial function in acute myocardial infarction [J]. Am Heart J, 1990, 119 (): 248.
9Gufinkel EP, Manos EJ, Mefail RI. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent isehemia [J]. J Am Coll Cardiol, 1995, 26: 313.
10Engelberg H, Heparin. Heparin fractions and the aterosclerotic process [J]. Semin Thromb Hemost, 1985, 11: 48-55.
